NUTX at a glance
Nutex Health Inc. (NUTX, SEC CIK 1479681) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 17, 2026 and Form 4 insider filings as recently as September 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Nutex Health Inc. (NUTX) reported revenue of $875.3 million (up 82.4% from FY2024) and net income of $70.8 million. Diluted EPS was $10.48.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Nutex Health Inc. (NUTX) shares worth $243.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Saunders Scott J on September 18, 2026 of 203 shares at $214.25 per share.
- In the last 90 days, NUTX insiders reported 0 open-market purchases ($0) and 1 open-market sale ($43K) on Form 4, a net sale of $43K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $875.3M
- +82.4% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$43K
- 13F holders
- 26 funds
- $243.9M · +0 vs prior quarter
- Latest 8-K
- Nov 17, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Cybersecurity incident: August 2026 unauthorized access and exfiltration of patient, employee, provider, business and financial data
- Legal exposure: putative class actions filed in Southern District of Texas over alleged inadequate security measures
- Regulatory compliance: HIPAA, Texas privacy laws, Senate Bill 1188 and SEC cybersecurity rules create evolving obligations
- Operational risk: third-party technology failures could disrupt systems and expose sensitive information
- Financial risk: remediation costs and liabilities may exceed insurance coverage
Management Discussion & Analysis
- Revenue $217.6M, down $50.2M YoY from $267.8M, driven by hospital revenue decline
- Operating margin 35.4% vs 48.7% YoY, net income margin 26.4% vs 36.1%
- Best segment: population health revenue $8.5M vs $7.6M; worst: hospital revenue $209.1M vs $260.2M
- Cash $249.9M vs $185.6M at December 31, 2025; operating cash flow $188.1M
- Headwinds: IDR volatility, regulatory changes, cybersecurity incident, uncertain enforcement of unpaid awards
AI summary of the NUTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Special cash dividend $2.00 per share, Nutex Health’s first as a public company
- Record date November 30, 2026, with payment scheduled for December 14, 2026
Item 8.01: Other Events
- Special cash dividend: $2.00 per share, payable December 14, 2026
- Record date November 30, 2026, determining shareholder eligibility
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results announced for the quarter ended September 30, 2026
- Investor-relevant financial and operating details contained in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q3 revenue fell 18.7% to $217.6 million, while net income declined to $40.2 million from $55.4 million
- Nine-month revenue decreased 10.9% to $644.9 million, despite net income rising to $152.9 million from $59.0 million
Item 8.01: Other Events
- Cybersecurity event update issued September 10, 2026
- Exhibit 99.1 contains the substantive incident details and potential shareholder impact
AI summaries of NUTX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NUTX
Don't miss the next NUTX filing
- Alerts as it files. A push when NUTX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NUTX, by share count.
- Ask anything. An AI agent that reads every NUTX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Saunders Scott J | Sell | Sep 18, 2026 | 203 | $214.25 |
| Saunders Scott J | M | Jul 31, 2026 | 603 | - |
| Jaumot Frank E | M | Jul 31, 2026 | 603 | - |
| Grenas Cheryl Yvonne | M | Jul 31, 2026 | 603 | - |
| Reed Michael Lee | M | Jul 31, 2026 | 603 | - |
| Spears Kelvin | J | Jun 4, 2026 | 2,519 | - |
| Vo Thomas T. | J | May 28, 2026 | 75,747 | - |
| Saunders Scott J | A | Apr 23, 2026 | 823 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $479.9M | $875.3M |
| Gross Profit | - | $196.3M | $444.3M |
| Operating Income | - | $130.6M | $275.6M |
| Net Income | - | $52.2M | $70.8M |
| Gross Margin | - | 40.9% | 50.8% |
| Op. Margin | - | 27.2% | 31.5% |
| Net Margin | - | 10.9% | 8.1% |
| Balance Sheet | |||
| Total Assets | $398.2M | $655.3M | $918.5M |
| Equity | - | $146.3M | $329.4M |
| ROE | - | 35.7% | 21.5% |
| Per Share | |||
| EPS | - | $9.71 | $10.48 |
| Cash Flow | |||
| Operating CF | - | $23.2M | $248.1M |
| CapEx | $9.5M | $2.3M | $2.5M |
Source: XBRL data in Nutex Health Inc. (NUTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate NUTX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $243.9M |
| Q2 2026 | 26 | $205.6M |
| Q1 2026 | 25 | $104.9M |
| Q4 2025 | 24 | $156.0M |
| Q3 2025 | 21 | $97.7M |
| Q2 2025 | 20 | $88.1M |
| Q1 2025 | 10 | $13.1M |
| Q4 2024 | 6 | $5.8M |
- Dimensional Fund Advisors+22.3K (+232%)
- Citigroup+14.4K (+555%)
- Vanguard Portfolio Management LLC+13.3K (+38%)
- Morgan Stanley+8.5K (+44%)
- Invesco Ltd+7.9K (+152%)
- Millennium Management−39.7K (-76%)
- D.E. Shaw & Co−25.1K (-26%)
- Vanguard Capital Management LLC−17.8K (-8%)
- Goldman Sachs Group−13.5K (-26%)
- Citadel Advisors LLC−13.2K (-72%)
- Prudential Financial+3.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 158 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NUTX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 17, 2026 | - | Analysis | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Sep 18, 2026 | - | - | - |
| 8-K | Sep 11, 2026 | - | Analysis | - |
| 8-K | Aug 31, 2026 | - | Analysis | - |
| 8-K | Aug 24, 2026 | - | Analysis | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 8-K | Jul 21, 2026 | - | Analysis | - |
| 4 | Jun 4, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 30, 2026 | - | Analysis | - |
| SC 13G | Apr 27, 2026 | - | - | |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 24, 2026 | - | - | - |
| 8-K | Apr 23, 2026 | - | Analysis | - |
Related Information Technology companies
- ACN · AccentureServices-Business Services, NEC
- ACVA · ACV Auctions Inc.Services-Business Services, NEC
- ADV · Advantage Solutions Inc.Services-Business Services, NEC
- AKAM · Akamai TechnologiesServices-Business Services, NEC
- BABA · Alibaba Group Holding LtdServices-Business Services, NEC
- ALIT · Alight, Inc. / DelawareServices-Business Services, NEC
- CASS · CASS INFORMATION SYSTEMS INCServices-Business Services, NEC
- CBZ · CBIZ, Inc.Services-Business Services, NEC
NUTX SEC filings: frequently asked questions
Are NUTX insiders buying or selling?
In the last 90 days, Nutex Health Inc. (NUTX) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $43,493 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold NUTX stock?
As of September 30, 2026, the largest Nutex Health Inc. (NUTX) holders among the 13F filers tracked by SignalX were BlackRock ($83.4 million), Vanguard Capital Management LLC ($41.9 million), State Street Corp ($28.6 million), D.E. Shaw & Co ($15.3 million), Vanguard Portfolio Management LLC ($10.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NUTX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Nutex Health Inc. (NUTX) reported revenue of $875.3 million (up 82.4% from FY2024) and net income of $70.8 million. Diluted EPS was $10.48. The figures come from the XBRL data in the 10-K.
What did NUTX report in its latest 8-K?
Nutex Health Inc. (NUTX) filed an 8-K on November 17, 2026 reporting Item 8.01 (Other Events). Special cash dividend $2.00 per share, Nutex Health’s first as a public company.
What are the latest NUTX SEC filings?
Nutex Health Inc. (NUTX) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 17, 2026 and a Form 4 insider filing on September 18, 2026.
What is NUTX's SEC CIK number?
Nutex Health Inc. (NUTX)'s SEC Central Index Key (CIK) is 1479681. EDGAR lists every NUTX filing under that number.
Ask anything about NUTX
The research agent reads NUTX's filings, financials, insider trades and 13F holders, then answers with sources.